Becton Dickinson & Co (NYSE:BDX)
$ 221.9 -0.08 (-0.04%) Market Cap: 64.16 Bil Enterprise Value: 82.13 Bil PE Ratio: 37.36 PB Ratio: 2.48 GF Score: 85/100

Becton Dickinson and Co at UBS Genomics 2.0 and Medtech Innovations Summit (Virtual) Transcript

Aug 13, 2020 / 07:30PM GMT
Release Date Price: $255.76 (+1.99%)
Matthew Charles Taylor;Thomas
UBS Investment Bank, Research Division - Equity Research Analyst of Medical Supplies & Devices

Great. Good afternoon, everyone. Welcome to our next session here in the MedTech Innovations Virtual Summit. I'm Matt Taylor, UBS' U.S. medical supplies and devices analyst and really pleased to be joined by management from Becton, Dickinson.

We're calling this session Fueling Innovation Since 1897, which is not something that we could say for, I think, any other company that we cover, so a long history here.

And we're very pleased to be joined today by Tom Polen, who's the President and CEO of BD; and also, we have Patrick Kaltenbach, who's the EVP and President of the Life Sciences segment.

So we'll have a robust fireside discussion with the group here focusing in and out on overall Becton innovations but also specifically on some in life sciences. And it's a great opportunity to get a kind of drill down on that segment as well.

So Tom and Patrick, thank you so much for joining us today. And thanks for spending the time.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot